Literature DB >> 16129700

Proteomic determination of widespread detergent-insolubility including Abeta but not tau early in the pathogenesis of Alzheimer's disease.

Randall L Woltjer1, P J Cimino, Angela M Boutté, Aimee M Schantz, Kathleen S Montine, Eric B Larson, Thomas Bird, Joseph F Quinn, Jing Zhang, Thomas J Montine.   

Abstract

Biochemical characterization of the major detergent-insoluble proteins that comprise hallmark histopathologic lesions initiated the molecular era of Alzheimer's disease (AD) research. Here, we reinvestigated detergent-insoluble proteins in AD using modern proteomic techniques. Using liquid chromatography (LC)-mass spectrometry (MS)-MS-based proteomics, we robustly identified 125 proteins in the detergent-insoluble fraction of late-onset AD (LOAD) temporal cortex that included several proteins critical to Abeta production, components of synaptic scaffolding, and products of genes linked to an increased risk of LOAD; we verified 15 of 15 of these proteins by Western blot. Following multiple analyses, we estimated that these represent ~80% of detergent-insoluble proteins in LOAD detectable by our method. Abeta, tau, and 7 of 8 other newly identified detergent-insoluble proteins were disproportionately increased in temporal cortex from patients with LOAD and AD derived from mutations in PSEN1 and PSEN2; all of these except tau were elevated in individuals with prodromal dementia, while none except Abeta were elevated in aged APPswe mice. These results are consistent with the amyloid hypothesis of AD and extend it to include widespread protein insolubility, not exclusively Abeta insolubility, early in AD pathogenesis even before the onset of clinical dementia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16129700     DOI: 10.1096/fj.05-4263fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  26 in total

1.  Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease.

Authors:  Randall L Woltjer; Kevin Duerson; Joseph M Fullmer; Paramita Mookherjee; Allison M Ryan; Thomas J Montine; Jeffrey A Kaye; Joseph F Quinn; Lisa Silbert; Deniz Erten-Lyons; James B Leverenz; Thomas D Bird; David V Pow; Kohichi Tanaka; G Stennis Watson; David G Cook
Journal:  J Neuropathol Exp Neurol       Date:  2010-07       Impact factor: 3.685

2.  Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow.

Authors:  C Dirk Keene; Rubens C Chang; Americo H Lopez-Yglesias; Bryan R Shalloway; Izabella Sokal; Xianwu Li; Patrick J Reed; Lisa M Keene; Kathleen S Montine; Richard M Breyer; Jason K Rockhill; Thomas J Montine
Journal:  Am J Pathol       Date:  2010-06-03       Impact factor: 4.307

3.  Aberrant accrual of BIN1 near Alzheimer's disease amyloid deposits in transgenic models.

Authors:  Pierre De Rossi; Robert J Andrew; Timothy F Musial; Virginie Buggia-Prevot; Guilian Xu; Moorthi Ponnusamy; Han Ly; Sofia V Krause; Richard C Rice; Valentine de l'Estoile; Tess Valin; Someya Salem; Florin Despa; David R Borchelt; Vytas P Bindokas; Daniel A Nicholson; Gopal Thinakaran
Journal:  Brain Pathol       Date:  2018-12-27       Impact factor: 6.508

4.  Quantitative proteomics identifies surfactant-resistant alpha-synuclein in cerebral cortex of Parkinsonism-dementia complex of Guam but not Alzheimer's disease or progressive supranuclear palsy.

Authors:  Wan Yang; Randall L Woltjer; Izabela Sokal; Catherine Pan; Yan Wang; Mary Brodey; Elaine R Peskind; James B Leverenz; Jing Zhang; Daniel P Perl; Douglas R Galasko; Thomas J Montine
Journal:  Am J Pathol       Date:  2007-08-03       Impact factor: 4.307

Review 5.  Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies.

Authors:  Aaron M Swomley; Sarah Förster; Jierel T Keeney; Judy Triplett; Zhaoshu Zhang; Rukhsana Sultana; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2013-10-09

Review 6.  Proteomics of human neurodegenerative diseases.

Authors:  Jing Zhang; C Dirk Keene; Catherine Pan; Kathleen S Montine; Thomas J Montine
Journal:  J Neuropathol Exp Neurol       Date:  2008-10       Impact factor: 3.685

7.  Amyloid-β1-42 slows clearance of synaptically released glutamate by mislocalizing astrocytic GLT-1.

Authors:  Annalisa Scimemi; James S Meabon; Randall L Woltjer; Jane M Sullivan; Jeffrey S Diamond; David G Cook
Journal:  J Neurosci       Date:  2013-03-20       Impact factor: 6.167

Review 8.  New insight into neurodegeneration: the role of proteomics.

Authors:  Ramavati Pal; Guido Alves; Jan Petter Larsen; Simon Geir Møller
Journal:  Mol Neurobiol       Date:  2013-12-10       Impact factor: 5.590

9.  Changes in proteome solubility indicate widespread proteostatic disruption in mouse models of neurodegenerative disease.

Authors:  Michael C Pace; Guilian Xu; Susan Fromholt; John Howard; Keith Crosby; Benoit I Giasson; Jada Lewis; David R Borchelt
Journal:  Acta Neuropathol       Date:  2018-08-23       Impact factor: 17.088

10.  Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease.

Authors:  Patrick J Cimino; Yue Yang; Xianwu Li; Jake F Hemingway; Makenzie K Cherne; Shawn B Khademi; Yoshinori Fukui; Kathleen S Montine; Thomas J Montine; C Dirk Keene
Journal:  Exp Mol Pathol       Date:  2013-01-11       Impact factor: 3.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.